Zhu, Z and Li, J and Ruan, G and Wang, G and Huang, C and Ding, C, Investigational drugs for the treatment of osteoarthritis, an update on recent developments, Expert opinion on investigational drugs, 27, (11) pp. 881-900. ISSN 1354-3784 (2018) [Refereed Article]
© 2018 Informa UK Limited, trading as Taylor & Francis Group
Areas Covered: This review will discuss recent development of agents for the treatment of OA, updating our previous narrative review published in 2015. They include drugs for controlling local and systemic inflammation, regulating articular cartilage, targeting subchondral bone, and relieving pain.
Expert Opinion: Although new OA drugs such as monoclonal antibodies have shown marked effects and favorable tolerance, current treatment options for OA remain limited. The authors believe there is no miracle drug that can be used for all OA patients'; treatment and disease stage is crucial for the effectiveness of drugs. Therefore, early diagnosis, phenotyping OA patients and precise therapy would expedite the development of investigational drugs targeting at symptoms and disease progression of OA.
|Item Type:||Refereed Article|
|Keywords:||ADAMTS, MMP inhibitors, TNF inhibitors, growth factors, inflammation, osteoarthritis, pain, subchondral bone, therapy|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Research Field:||Rheumatology and arthritis|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Ding, C (Professor Chang-Hai Ding)|
|Web of Science® Times Cited:||21|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page